Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Nafamostat Mesylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Talphera Unveils Q1 2026 Financials And Corporate Update
    Talphera Unveils Q1 2026 Financials And Corporate Update

    14 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-announces-first-quarter-2026-financial-results-and-provides-corporate-update-302769923.html

    PR NEWSWIRE
    14 May 2026
    Share Share
    Ensysce Expands Overdose Protection Patent Coverage
    Ensysce Expands Overdose Protection Patent Coverage

    12 May 2026

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/ensysce-biosciences-announces-expansion-of-patent-protection-for-grou-1165814

    ACCESSWIRE
    12 May 2026
    Share Share
    Ensysce Biosciences Enhances Patent Protection For MPAR(R)
    Ensysce Biosciences Enhances Patent Protection For MPAR(R)

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/ensysce-biosciences-announces-broader-patent-protection-for-groundbreaking-mpar-r-overdose-protecti

    PHARMIWEB
    02 Dec 2025
    Share Share
    Talphera to Host Q4 2024 Financial Results Call on March 31, 2025
    Talphera to Host Q4 2024 Financial Results Call on March 31, 2025

    26 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/talphera-to-host-fourth-quarter-and-full-year-2024-financial-results-and-corporate-update-call-and-webcast-on-monday-march-31-2025-302412500.html

    PR NEWSWIRE
    26 Mar 2025
    Share Share
    Daiichi Sankyo discontinues development of Nafamostat in Japan
    Daiichi Sankyo discontinues development of Nafamostat in Japan

    18 Jun 2021

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/25/18382/daiichi-sankyo-discontinues-development-of-nafamostat-in-japan-for-covid-19-treatment.html

    BIOSPECTRUM ASIA
    18 Jun 2021
    Share Share
    Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formu
    Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formu

    30 Mar 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=136431&sid=2

    PHARMABIZ
    30 Mar 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.